Drugs News and Research

RSS

Antidepressants may increase heart attack or stroke risk in men: Study

...

3 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Discovery of 4 new genes associated with Alzheimer's

In the largest study of its kind, researchers from a consortium led by the University of Pennsylvania School of Medicine, Boston University School of Medicine and the University of Miami identified four new genes linked to Alzheimer's disease. Each gene individually adds to the risk of having this common form of dementia later in life. These new genes offer a portal into what causes Alzheimer's disease and is a major advance in the field.

3 Apr 2011

Stem Cell Action Coalition issues urgent appeal to Minnesota Governor for SCNT research

The Stem Cell Action Coalition issued an urgent appeal to Minnesota Governor Mark Dayton to veto any legislation that contains any impediment to lawful embryonic stem cell research in the state.

2 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Experts must monitor new antiviral compounds for HCV treatment

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimised.

2 Apr 2011

Sunshine Biopharma to present new Adva-27a data against cancer at AACR meeting

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that they will be presenting scientific data at the American Association for Cancer Research Meeting April 2-6, 2011 in Orlando Florida.

2 Apr 2011

The Economist examines factors contributing to antimicrobial resistance

"Antibiotic resistance has now become a costly and dangerous problem," The Economist writes in an article examining the factors that have contributed to the global rise of antibiotic resistant bacteria, ahead of next week's World Health Day dedicated to the issue.

2 Apr 2011

Array BioPharma to unveil new findings about its anti-cancer programs at AACR Annual Meeting

Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

New research identifies diverse barriers to breast cancer screening and treatment

A landmark breast health care publication reveals a multitude of barriers that keep women of developing nations from being screened and treated for breast cancer - but offers tools to help countries improve their breast care programs.

2 Apr 2011

Rsearchers define new step that controls programmed cell death in cancer cells

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death.

2 Apr 2011

Recent releases in Global Health

A Lancet Infectious Diseases editorial describes the growing public concerns over a global rise in antimicrobial resistance. "Bearing in mind that our objective is to contain antibiotic resistance rather than eradicate it, several policies could be adopted to help guarantee a future for antibiotics," the editorial states, adding, "We need reliable data to tackle antibiotic resistance.

2 Apr 2011

Loss of SKIP sensitizes cancer cells to apoptotic effects of DNA damage-inducing anticancer drugs

When cells find themselves in a tight spot, the cell cycle regulator p21 halts the cell cycle, buying cells time to repair the damage, or if all else fails, to initiate programmed cell death. In contrast to other stress-induced genes, which dispense with the regular transcriptional entourage, p21Cip1 still requires SKIP, a transcription elongation factor that also helps with the editing of transcripts, to be expressed, found researchers at the Salk Institute for Biological Studies.

2 Apr 2011

Interdisciplinary approach leads to breakthroughs in bio nanotechnology research

Focusing on interdisciplinary research is now leading to breakthroughs in bio nanotechnology research. A new method for drug development has become a reality.

2 Apr 2011

Minnesota medical spending reached $17.4 billion in 2010

Health costs per person in Minnesota rose only 2.6 percent in 2010, about half the national average. Key factors in controlling costs were innovations by Minnesota's health plans – for example, more effective management of care for those with chronic diseases – and reduced demand for health care in a slow economy.

2 Apr 2011

University of Houston part of multi-investigator $5.2M CPRIT award for prostate cancer research

A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

2 Apr 2011

The Wall Street Journal: Pfizer, Glaxo detail fees paid to doctors

Pfizer Inc. paid $177 million and GlaxoSmithKline PLC paid $85 million during 2010 to U.S. doctors and institutions for their work on clinical trials, consulting, speaking and other items, the companies disclosed Thursday.

1 Apr 2011

Ther-Rx Corporation announces important initiative to reduce cost of Makena

As part of its ongoing efforts to ensure that high-risk women have access to FDA-approved Makena instead of unapproved, unregulated compounded drugs, Ther-Rx Corporation, a subsidiary of K-V Pharmaceutical Company, announced today important initiatives to reduce the cost of Makena (hydroxyprogesterone caproate injection) and encourage stakeholders to provide timely access to this important FDA-approved medication.

1 Apr 2011

Geisinger expert offers advice on how to manage child's asthma

Asthma is the leading cause of hospital visits and missed school days in children, according to the National Institute of Health. A chronic condition, pediatric asthma requires continual care to prevent serious, life-threatening asthma attacks.

1 Apr 2011